1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	increasing	_	_	VBG	_	_	_	_	_
3	resistances	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	pathogenic	_	_	JJ	_	_	_	_	_
6	bacteria	_	_	NNS	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	one	_	_	CD	_	_	_	_	_
9	great	_	_	JJ	_	_	_	_	_
10	problem	_	_	NN	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	worldwide	_	_	JJ	_	_	_	_	_
13	health	_	_	NN	_	_	_	_	_
14	policy	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	because	_	_	IN	_	_	_	_	_
17	it	_	_	PRP	_	_	_	_	_
18	means	_	_	VBZ	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	threat	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	humanity	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Pathogenic	_	_	JJ	_	_	_	_	_
2	bacteria	_	_	NNS	_	_	_	_	_
3	can	_	_	MD	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	found	_	_	VBN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	human	_	_	JJ	_	_	_	_	_
8	surroundings	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	drinking	_	_	NN	_	_	_	_	_
12	water	_	_	NN	_	_	_	_	_
13	may	_	_	MD	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	contaminated	_	_	VBN	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	bacteria	_	_	NNS	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	developing	_	_	VBG	_	_	_	_	_
20	countries	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	last	_	_	JJ	_	_	_	_	_
4	century	_	_	NN	_	_	_	_	_
5	sufficient	_	_	JJ	_	_	_	_	_
6	antibacterials	_	_	NNS	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	available	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	effectively	_	_	RB	_	_	_	_	_
11	treat	_	_	VB	_	_	_	_	_
12	infections	_	_	NNS	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	those	_	_	DT	_	_	_	_	_
15	various	_	_	JJ	_	_	_	_	_
16	bacteria	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Beside	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	standard	_	_	JJ	_	_	_	_	_
4	antibacterials	_	_	NNS	_	_	_	_	_
5	like	_	_	IN	_	_	_	_	_
6	penicillin	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	reserve	_	_	NN	_	_	_	_	_
9	antibiotics	_	_	NNS	_	_	_	_	_
10	have	_	_	VBP	_	_	_	_	_
11	been	_	_	VBN	_	_	_	_	_
12	discovered	_	_	VBN	_	_	_	_	_
13	from	_	_	IN	_	_	_	_	_
14	natural	_	_	JJ	_	_	_	_	_
15	sources	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	were	_	_	VBD	_	_	_	_	_
18	resynthesized	_	_	VBN	_	_	_	_	_
19	by	_	_	IN	_	_	_	_	_
20	industrial	_	_	JJ	_	_	_	_	_
21	companies	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	abuse	_	_	NN	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	overuse	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	those	_	_	DT	_	_	_	_	_
9	antibiotics	_	_	NNS	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	one	_	_	CD	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	reasons	_	_	NNS	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	present	_	_	JJ	_	_	_	_	_
18	crisis	_	_	NN	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	resistant	_	_	JJ	_	_	_	_	_
21	bacteria	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	case	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	viral	_	_	JJ	_	_	_	_	_
6	infections	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	antibiotics	_	_	NNS	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	often	_	_	RB	_	_	_	_	_
11	prescribed	_	_	VBN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	case	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	existing	_	_	VBG	_	_	_	_	_
6	sensitivities	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	bacteria	_	_	NN	_	_	_	_	_
9	towards	_	_	IN	_	_	_	_	_
10	standard	_	_	JJ	_	_	_	_	_
11	antibiotics	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	novel	_	_	JJ	_	_	_	_	_
14	reserve	_	_	NN	_	_	_	_	_
15	antibiotics	_	_	NNS	_	_	_	_	_
16	have	_	_	VBP	_	_	_	_	_
17	been	_	_	VBN	_	_	_	_	_
18	used	_	_	VBN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	clinics	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	bacteria	_	_	NNS	_	_	_	_	_
4	with	_	_	IN	_	_	_	_	_
5	contact	_	_	NN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	those	_	_	DT	_	_	_	_	_
8	antibiotics	_	_	NNS	_	_	_	_	_
9	like	_	_	IN	_	_	_	_	_
10	Staphylococcus	_	_	NNP	_	_	_	_	_
11	aureus	_	_	NN	_	_	_	_	_
12	on	_	_	IN	_	_	_	_	_
13	human	_	_	JJ	_	_	_	_	_
14	surfaces	_	_	NNS	_	_	_	_	_
15	like	_	_	IN	_	_	_	_	_
16	skin	_	_	NN	_	_	_	_	_
17	developed	_	_	VBD	_	_	_	_	_
18	early	_	_	JJ	_	_	_	_	_
19	resistances	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	misuse	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	antibiotics	_	_	NNS	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	also	_	_	RB	_	_	_	_	_
7	present	_	_	JJ	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	mast	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	poultry	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Those	_	_	DT	_	_	_	_	_
2	antibiotics	_	_	NNS	_	_	_	_	_
3	contaminate	_	_	VBP	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	environment	_	_	NN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	animal	_	_	NN	_	_	_	_	_
8	excretions	_	_	NNS	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	Finally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	industrial	_	_	JJ	_	_	_	_	_
4	waste	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	antibiotic	_	_	JJ	_	_	_	_	_
7	production	_	_	NN	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	pumped	_	_	VBN	_	_	_	_	_
10	into	_	_	IN	_	_	_	_	_
11	rivers	_	_	NNS	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	producing	_	_	VBG	_	_	_	_	_
14	countries	_	_	NNS	_	_	_	_	_
15	like	_	_	IN	_	_	_	_	_
16	India	_	_	NNP	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	bacteria	_	_	NNS	_	_	_	_	_
4	develop	_	_	VBP	_	_	_	_	_
5	resistance	_	_	NN	_	_	_	_	_
6	mechanisms	_	_	NNS	_	_	_	_	_
7	that	_	_	WDT	_	_	_	_	_
8	allow	_	_	VBP	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	spread	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	resistance	_	_	NN	_	_	_	_	_
13	genes	_	_	NNS	_	_	_	_	_
14	via	_	_	IN	_	_	_	_	_
15	plasmids	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	also	_	_	RB	_	_	_	_	_
19	between	_	_	IN	_	_	_	_	_
20	different	_	_	JJ	_	_	_	_	_
21	species	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	One	_	_	CD	_	_	_	_	_
2	other	_	_	JJ	_	_	_	_	_
3	problem	_	_	NN	_	_	_	_	_
4	that	_	_	WDT	_	_	_	_	_
5	contributes	_	_	VBZ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	present	_	_	JJ	_	_	_	_	_
9	antibiotic	_	_	JJ	_	_	_	_	_
10	crisis	_	_	NN	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	fact	_	_	NN	_	_	_	_	_
14	that	_	_	IN	_	_	_	_	_
15	pharmaceutical	_	_	JJ	_	_	_	_	_
16	companies	_	_	NNS	_	_	_	_	_
17	recently	_	_	RB	_	_	_	_	_
18	announced	_	_	VBD	_	_	_	_	_
19	that	_	_	IN	_	_	_	_	_
20	they	_	_	PRP	_	_	_	_	_
21	would	_	_	MD	_	_	_	_	_
22	no	_	_	RB	_	_	_	_	_
23	longer	_	_	RBR	_	_	_	_	_
24	invest	_	_	VB	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	development	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	novel	_	_	JJ	_	_	_	_	_
30	antibiotics	_	_	NNS	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	financial	_	_	JJ	_	_	_	_	_
3	outcome	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	development	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	life	_	_	NN	_	_	_	_	_
9	style	_	_	NN	_	_	_	_	_
10	drugs	_	_	NNS	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	much	_	_	RB	_	_	_	_	_
13	better	_	_	JJR	_	_	_	_	_
14	than	_	_	IN	_	_	_	_	_
15	that	_	_	DT	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	antibiotics	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Antibiotics	_	_	NNS	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	cheap	_	_	JJ	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	use	_	_	NN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	low-income	_	_	JJ	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	developing	_	_	VBG	_	_	_	_	_
13	countries	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Innovative	_	_	JJ	_	_	_	_	_
2	but	_	_	CC	_	_	_	_	_
3	vague	_	_	JJ	_	_	_	_	_
4	approaches	_	_	NNS	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	find	_	_	VB	_	_	_	_	_
7	novel	_	_	JJ	_	_	_	_	_
8	antibiotics	_	_	NNS	_	_	_	_	_
9	have	_	_	VBP	_	_	_	_	_
10	been	_	_	VBN	_	_	_	_	_
11	an	_	_	DT	_	_	_	_	_
12	influencing	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	bacterial	_	_	JJ	_	_	_	_	_
16	gene	_	_	NN	_	_	_	_	_
17	expression	_	_	NN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	modify	_	_	VB	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	bacterial	_	_	JJ	_	_	_	_	_
22	metabolism	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Such	_	_	PDT	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	modified	_	_	VBN	_	_	_	_	_
4	metabolism	_	_	NN	_	_	_	_	_
5	might	_	_	MD	_	_	_	_	_
6	lead	_	_	VB	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	novel	_	_	JJ	_	_	_	_	_
9	metabolic	_	_	JJ	_	_	_	_	_
10	products	_	_	NNS	_	_	_	_	_
11	which	_	_	WDT	_	_	_	_	_
12	have	_	_	VBP	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	identified	_	_	VBN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	tested	_	_	VBN	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	their	_	_	PRP$	_	_	_	_	_
20	antibacterial	_	_	JJ	_	_	_	_	_
21	properties	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Methods	_	_	NNS	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	alter	_	_	VB	_	_	_	_	_
4	gene	_	_	NN	_	_	_	_	_
5	expression	_	_	NN	_	_	_	_	_
6	may	_	_	MD	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	varied	_	_	VBN	_	_	_	_	_
9	growth	_	_	NN	_	_	_	_	_
10	conditions	_	_	NNS	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	microbial	_	_	JJ	_	_	_	_	_
14	co-culturing	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	various	_	_	JJ	_	_	_	_	_
17	bacteria	_	_	NNS	_	_	_	_	_
18	or	_	_	CC	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	fungi	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	bacteria	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Other	_	_	JJ	_	_	_	_	_
2	sources	_	_	NNS	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	identification	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	novel	_	_	JJ	_	_	_	_	_
8	antibiotics	_	_	NNS	_	_	_	_	_
9	have	_	_	VBP	_	_	_	_	_
10	been	_	_	VBN	_	_	_	_	_
11	plants	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	marine	_	_	JJ	_	_	_	_	_
14	invertebrates	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	insects	_	_	NNS	_	_	_	_	_
17	or	_	_	CC	_	_	_	_	_
18	amphibia	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Isolated	_	_	VBN	_	_	_	_	_
2	antimicrobial	_	_	JJ	_	_	_	_	_
3	peptides	_	_	NNS	_	_	_	_	_
4	from	_	_	IN	_	_	_	_	_
5	such	_	_	JJ	_	_	_	_	_
6	sources	_	_	NNS	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	long	_	_	RB	_	_	_	_	_
9	been	_	_	VBN	_	_	_	_	_
10	favored	_	_	VBN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	they	_	_	PRP	_	_	_	_	_
4	still	_	_	RB	_	_	_	_	_
5	hamper	_	_	VBP	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	various	_	_	JJ	_	_	_	_	_
8	problems	_	_	NNS	_	_	_	_	_
9	like	_	_	IN	_	_	_	_	_
10	proteolytic	_	_	JJ	_	_	_	_	_
11	instability	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	short	_	_	JJ	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	vivo	_	_	NN	_	_	_	_	_
16	half-lives	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	insufficient	_	_	JJ	_	_	_	_	_
19	solubility	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	poor	_	_	JJ	_	_	_	_	_
23	bioavailability	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Alternative	_	_	JJ	_	_	_	_	_
2	small-molecule	_	_	JJ	_	_	_	_	_
3	antibacterials	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	rare	_	_	JJ	_	_	_	_	_
6	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	own	_	_	VBP	_	_	_	_	_
3	promising	_	_	JJ	_	_	_	_	_
4	properties	_	_	NNS	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	oral	_	_	JJ	_	_	_	_	_
8	use	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	not	_	_	RB	_	_	_	_	_
13	expected	_	_	VBN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	show	_	_	VB	_	_	_	_	_
16	problems	_	_	NNS	_	_	_	_	_
17	reported	_	_	VBN	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	those	_	_	DT	_	_	_	_	_
20	antimicrobial	_	_	JJ	_	_	_	_	_
21	peptides	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Presently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	such	_	_	JJ	_	_	_	_	_
4	small-molecule	_	_	JJ	_	_	_	_	_
5	antibacterials	_	_	NNS	_	_	_	_	_
6	that	_	_	WDT	_	_	_	_	_
7	result	_	_	VBP	_	_	_	_	_
8	from	_	_	IN	_	_	_	_	_
9	synthetic	_	_	JJ	_	_	_	_	_
10	chemistry	_	_	NN	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	unknown	_	_	JJ	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	emerge	_	_	VB	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	novel	_	_	JJ	_	_	_	_	_
18	antibacterial	_	_	JJ	_	_	_	_	_
19	compound	_	_	NN	_	_	_	_	_
20	class	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	gained	_	_	VBD	_	_	_	_	_
3	access	_	_	NN	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	two	_	_	CD	_	_	_	_	_
6	novel	_	_	JJ	_	_	_	_	_
7	structurally-related	_	_	JJ	_	_	_	_	_
8	classes	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	small-molecule	_	_	JJ	_	_	_	_	_
11	antibacterials	_	_	NNS	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	reaction	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	substituted	_	_	VBN	_	_	_	_	_
17	indoles	_	_	NNS	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	thiophene	_	_	NN	_	_	_	_	_
20	dicarbaldehyde	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	various	_	_	JJ	_	_	_	_	_
4	composed	_	_	VBN	_	_	_	_	_
5	hybrid	_	_	JJ	_	_	_	_	_
6	molecules	_	_	NNS	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	yielded	_	_	VBN	_	_	_	_	_
9	from	_	_	IN	_	_	_	_	_
10	those	_	_	DT	_	_	_	_	_
11	indoles	_	_	NNS	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	benzothiophene	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Hybrid	_	_	JJ	_	_	_	_	_
2	molecules	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	antimicrobial	_	_	JJ	_	_	_	_	_
5	active	_	_	JJ	_	_	_	_	_
6	antibiotics	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	or	_	_	CC	_	_	_	_	_
9	antifungal	_	_	JJ	_	_	_	_	_
10	drugs	_	_	NNS	_	_	_	_	_
11	have	_	_	VBP	_	_	_	_	_
12	recently	_	_	RB	_	_	_	_	_
13	been	_	_	VBN	_	_	_	_	_
14	reviewed	_	_	VBN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	mostly	_	_	RB	_	_	_	_	_
3	consist	_	_	VBP	_	_	_	_	_
4	either	_	_	DT	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	two	_	_	CD	_	_	_	_	_
7	different	_	_	JJ	_	_	_	_	_
8	antibiotics	_	_	NNS	_	_	_	_	_
9	or	_	_	CC	_	_	_	_	_
10	antifungals	_	_	NNS	_	_	_	_	_
11	that	_	_	WDT	_	_	_	_	_
12	are	_	_	VBP	_	_	_	_	_
13	connected	_	_	VBN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	linker	_	_	NN	_	_	_	_	_
17	like	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	simple	_	_	JJ	_	_	_	_	_
20	carbon	_	_	NN	_	_	_	_	_
21	chain	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	So	_	_	RB	_	_	_	_	_
2	fluoroquinolone-oxazolidinone	_	_	NN	_	_	_	_	_
3	hybrids	_	_	NNS	_	_	_	_	_
4	reached	_	_	VBD	_	_	_	_	_
5	clinical	_	_	JJ	_	_	_	_	_
6	trials	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	novel	_	_	NN	_	_	_	_	_
9	1	_	_	CD	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	2	_	_	CD	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	3-triazole	_	_	JJ	_	_	_	_	_
14	antifungal	_	_	JJ	_	_	_	_	_
15	hybrids	_	_	NNS	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	8-aminoquinoline	_	_	NN	_	_	_	_	_
18	or	_	_	CC	_	_	_	_	_
19	dioxolane	_	_	NN	_	_	_	_	_
20	have	_	_	VBP	_	_	_	_	_
21	recently	_	_	RB	_	_	_	_	_
22	been	_	_	VBN	_	_	_	_	_
23	reported	_	_	VBN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	novel	_	_	NN	_	_	_	_	_
3	compound	_	_	NN	_	_	_	_	_
4	classes	_	_	NNS	_	_	_	_	_
5	were	_	_	VBD	_	_	_	_	_
6	tested	_	_	VBN	_	_	_	_	_
7	against	_	_	IN	_	_	_	_	_
8	prominent	_	_	JJ	_	_	_	_	_
9	Gram-positive	_	_	JJ	_	_	_	_	_
10	bacteria	_	_	NNS	_	_	_	_	_
11	that	_	_	WDT	_	_	_	_	_
12	are	_	_	VBP	_	_	_	_	_
13	associated	_	_	VBN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	severe	_	_	JJ	_	_	_	_	_
16	hospital	_	_	NN	_	_	_	_	_
17	infections	_	_	NNS	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	Staphylococcus	_	_	NNP	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	Enterococcus	_	_	NNP	_	_	_	_	_
22	strains	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	identified	_	_	VBD	_	_	_	_	_
3	first	_	_	JJ	_	_	_	_	_
4	lead	_	_	NN	_	_	_	_	_
5	compounds	_	_	NNS	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	promising	_	_	JJ	_	_	_	_	_
8	activities	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	confirmed	_	_	VBD	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	vitro	_	_	NN	_	_	_	_	_
14	results	_	_	NNS	_	_	_	_	_
15	first	_	_	RB	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	vivo	_	_	JJ	_	_	_	_	_
20	studies	_	_	NNS	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	selected	_	_	VBN	_	_	_	_	_
23	derivatives	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_

